Agios Pharmaceuticals, Inc. Common Stock AGIO
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:29:02.221Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:40:29.623766781Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:29:01.206319+00:00
Agios Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 29.08 | 49.7% | 13.8% | |||
| 25Δ | 30.19 | 47.9% | 11.0% | |||
| 30Δ | 37.06 | 51.3% | 15.1% | 30.82 | 47.2% | 9.9% |
| 35Δ | 35.74 | 47.3% | 11.5% | 31.45 | 46.5% | 8.9% |
| 40Δ | 34.80 | 44.1% | 9.2% | 32.08 | 45.7% | 7.8% |
| 45Δ | 34.34 | 42.1% | 8.4% | 32.70 | 45.0% | 6.7% |
| 50Δ | 33.89 | 40.0% | 7.6% | 33.33 | 44.2% | 5.6% |
| 55Δ | 33.43 | 37.9% | 6.7% | 33.96 | 43.5% | 4.5% |
| 60Δ | 32.97 | 35.8% | 5.9% | 34.58 | 42.8% | 3.4% |
| 65Δ | 32.51 | 33.7% | 5.1% | |||
| 70Δ | 32.06 | 31.6% | 4.3% | |||
| 75Δ | 31.60 | 29.5% | 3.5% | 41.57 | 85.8% | 3.0% |
| 80Δ | 31.14 | 27.4% | 2.7% | 46.03 | 102.0% | 2.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.08
- IV
- 49.7%
- B/E move
- 13.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.19
- IV
- 47.9%
- B/E move
- 11.0%
30Δ
- Pseudo strike
- 37.06
- IV
- 51.3%
- B/E move
- 15.1%
- Pseudo strike
- 30.82
- IV
- 47.2%
- B/E move
- 9.9%
35Δ
- Pseudo strike
- 35.74
- IV
- 47.3%
- B/E move
- 11.5%
- Pseudo strike
- 31.45
- IV
- 46.5%
- B/E move
- 8.9%
40Δ
- Pseudo strike
- 34.80
- IV
- 44.1%
- B/E move
- 9.2%
- Pseudo strike
- 32.08
- IV
- 45.7%
- B/E move
- 7.8%
45Δ
- Pseudo strike
- 34.34
- IV
- 42.1%
- B/E move
- 8.4%
- Pseudo strike
- 32.70
- IV
- 45.0%
- B/E move
- 6.7%
50Δ
- Pseudo strike
- 33.89
- IV
- 40.0%
- B/E move
- 7.6%
- Pseudo strike
- 33.33
- IV
- 44.2%
- B/E move
- 5.6%
55Δ
- Pseudo strike
- 33.43
- IV
- 37.9%
- B/E move
- 6.7%
- Pseudo strike
- 33.96
- IV
- 43.5%
- B/E move
- 4.5%
60Δ
- Pseudo strike
- 32.97
- IV
- 35.8%
- B/E move
- 5.9%
- Pseudo strike
- 34.58
- IV
- 42.8%
- B/E move
- 3.4%
65Δ
- Pseudo strike
- 32.51
- IV
- 33.7%
- B/E move
- 5.1%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 32.06
- IV
- 31.6%
- B/E move
- 4.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 31.60
- IV
- 29.5%
- B/E move
- 3.5%
- Pseudo strike
- 41.57
- IV
- 85.8%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 31.14
- IV
- 27.4%
- B/E move
- 2.7%
- Pseudo strike
- 46.03
- IV
- 102.0%
- B/E move
- 2.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 110.84% | |
| 66.15% | |
| 64.77% | |
| 70.09% | |
| 66.02% | |
| 60.58% | |
| 65.89% | |
| 63.47% | |
| 73.78% | |
| 70.55% | |
| 70.16% | |
| 71.22% | |
| 77.09% | |
| 75.66% | |
| 80.46% | |
| 76.46% | |
| 73.83% | |
| 75.93% | |
| 76.26% | |
| 76.94% | |
| 78.44% | |
| 93.22% | |
| 88.79% | |
| 81.44% | |
| 86.04% | |
| 88.52% | |
| 87.99% | |
| 147.79% | |
| 171.31% | |
| 94.45% | |
| 95.99% | |
| 81.69% | |
| 85.68% | |
| 83.74% | |
| 84.42% | |
| 78.63% | |
| 78.99% | |
| 76.53% | |
| 75.66% | |
| 69.74% |
Biotechnology
AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve…
More →ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington,…
More →ALEC
Description unavailable
More →ALLO
Description unavailable
More →ALMS
Description unavailable
More →